Viganò L, Torzilli G, Cimino M, Imai K, Vibert E, Donadon M, Castaing D, Adam R
Department of Surgery, Division of Hepatobiliary & General Surgery, Humanitas Research Hospital, Humanitas University, Rozzano, Milano, Italy.
Department of Surgery, Division of Hepatobiliary & General Surgery, Humanitas Research Hospital, Humanitas University, Rozzano, Milano, Italy.
Eur J Surg Oncol. 2016 Sep;42(9):1385-93. doi: 10.1016/j.ejso.2016.03.020. Epub 2016 Apr 26.
Two-stage hepatectomy (TSH) is the present standard for multiple bilobar colorectal liver metastases (CLM), but 25-35% of patients fail to complete the scheduled procedure (drop-out). To elucidate if drop-out of TSH is a patient selection (as usually considered) or a loss of chance.
All the consecutive patients scheduled for a TSH at the Paul Brousse Hospital between 2000 and 2012 were considered. TSH patients were matched 1:1 with patients receiving a one-stage ultrasound-guided hepatectomy (OSH) at the Humanitas Research Hospital in the same period. Matching criteria were: primary tumor N status; timing of CLM diagnosis; CLM number and distribution into the liver.
Sixty-three pairs of patients were analyzed. Demographic and tumor characteristics were similar (median 7 CLM), except for more chemotherapy lines and adjuvant chemotherapy in TSH. Drop-out rate of TSH was 38.1% (0% of OSH). The two groups had similar R0 resection rate (19.0% OSH vs. 15.9% TSH). OSH and completed TSH had similar five-year survival (from CLM diagnosis 49.8% vs. 49.7%, from liver resection 36.1% vs. 44.3%), superior to drop-out (10% three-year survival, p < 0.001). OSH and completed TSH had similar recurrence-free survival (at three years 21.7% vs. 20.5%) and recurrence sites. The completion of resection (drop-out vs. OSH/completed TSH) was the only independent prognostic factor (p = 0.003).
Drop-out of TSH could be a loss of chance rather than a criteria for patient selection. "Unselected" OSH patients had the same outcomes of selected patients who completed TSH. A complete resection is the main determinant of prognosis.
两阶段肝切除术(TSH)是目前治疗多叶结直肠癌肝转移(CLM)的标准方法,但25%-35%的患者未能完成预定手术(退出)。为了阐明TSH的退出是患者选择问题(如通常所认为的)还是机会丧失。
纳入2000年至2012年期间在保罗·布罗斯医院计划接受TSH的所有连续患者。将TSH患者与同期在胡马纳塔斯研究医院接受一期超声引导肝切除术(OSH)的患者按1:1进行匹配。匹配标准为:原发肿瘤N分期;CLM诊断时间;CLM数量及在肝脏中的分布。
分析了63对患者。除TSH组化疗疗程更多和接受辅助化疗外,人口统计学和肿瘤特征相似(CLM中位数为7个)。TSH的退出率为38.1%(OSH为0%)。两组的R0切除率相似(OSH为19.0%,TSH为15.9%)。OSH和完成TSH的患者五年生存率相似(从CLM诊断起分别为49.8%和49.7%,从肝切除起分别为36.1%和44.3%),优于退出患者(三年生存率为10%,p<0.001)。OSH和完成TSH的患者无复发生存率相似(三年时分别为21.7%和20.5%),复发部位也相似。手术完成情况(退出与OSH/完成TSH)是唯一的独立预后因素(p=0.003)。
TSH的退出可能是机会丧失而非患者选择标准。“未选择”的OSH患者与完成TSH的选择患者有相同的结局。完整切除是预后的主要决定因素。